@FiercePharma: Top-read special report this weekend: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma
@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI Friday: New problems at $GSK flu vaccine plant will impact U.S., Canada orders. Article | Follow @CarlyHFierce
> After several years of litigation over femur fractures allegedly caused by osteoporosis drug Fosamax, a New Jersey federal judge has ordered maker Merck ($MRK) and plaintiffs to mediate. Report (sub. req.)
> Valeant Pharmaceuticals ($VRX) will open new manufacturing lines at Bausch + Lomb, with the $106 million addition is expected to result in 100 new jobs. More
> India's Elder Pharma is looking to increase its footprint in the dermatology space. Report
> Endo ($ENDP) has launched an authorized generic of testosterone gel Fortesta. Release
> A pair of long-term studies has confirmed the safety of Bayer's Adempas in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Release
Medical Device News
@FierceMedDev: ICYMI: Medtronic receives CE mark for upgraded CoreValve TAVR. Report | Follow @FierceMedDev
@VarunSaxena2: UPDATED with CEO comments: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? Report | Follow @VarunSaxena2
@MichaelGFierce: CYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. More | Follow @MichaelGFierce
@EmilyWFierce: French devicemaker Carmat outfits second patient with artificial heart, forges ahead with clinical trials. Story | Follow @EmilyWFierce
> J&J ordered to fork over $3.27M in vaginal mesh case. Article
> FDA clears Otoharmonic's iPad/iPod app that treats tinnitus. Story
Biotech News
@FierceBiotech: You buy a Type 1 diabetes drug in PhIII for $20M in cash and stock and you're "shocked" by trial fraud. Really $HPTX? You didn't suspect? | Follow @FierceBiotech
@JohnCFierce: Running some readership numbers for the year. @FierceBiotech 70% North America, 18% Europe and 10% Asia, which is a bump for Europe. | Follow @JohnCFierce
@DamianFierce: Hyperion says it was duped into signing a $570M deal for an Israeli biotech. Story | Follow @DamianFierce
@EmilyMFierce: More misplaced pathogens, toxins found in NIH, FDA labs. More from The Washington Post | Follow @EmilyMFierce
> AstraZeneca's self-styled 'blockbuster' benralizumab tanks in severe COPD study. More
> FDA warning dampens Keryx's parade for newly approved kidney drug. Report
> A respiratory expert undermines GSK's case for new asthma drug mepolizumab. Article
CRO News
> AMRI buys into proteomics to expand its discovery services. Report
> Big Pharma supergroup dishes on de-personalizing clinical data. Story
> CRO Ricerca plans to shed its staff if it can't find a buyer. Article
> Venn lands a $3.1M deal to study a bioresorbable stent. Item
> Catalent eyes another big year after a blockbuster IPO. More
Biotech IT News
> Edico sells its first Dragen bioinformatics processor. More
> George Church talks open data with The Economist. Item
> Propeller Health raises $14.5M to develop its smart inhaler. News
> Apple bars health apps from using iCloud, acting as medical devices. Story
> Big Pharma consortium releases guide to redacting trial data. Article
Animal Health News
> USDA gives conditional approval for Zoetis PEDv vaccine. More
> South Korea lifts ban on zilpaterol feed additives in beef. Report
> Ceva Animal Health expanding into swine market. Story
> Perdue says its chick hatcheries are now antibiotic-free. Article
> Kentucky Horse Racing Commission looking into regulating compounders. Item
And Finally... Why aren't Google ($GOOG) and AbbVie ($ABBV) doing their anti-aging research in AbbVie's home state of Illinois? Story